Edition:
Deutschland

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,776JPY
3 Jul 2020
Change (% chg)

¥16 (+0.88%)
Prev Close
¥1,760
Open
¥1,766
Day's High
¥1,776
Day's Low
¥1,759
Volume
2,253,200
Avg. Vol
6,894,573
52-wk High
¥1,987
52-wk Low
¥1,375

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main... (more)

Buy/Sell

Sell Hold Buy
2.17 Mean rating from 12 analysts

Overall

Beta: 0.60
Market Cap(Mil.): ¥3,012,207.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.34

Japanese shares regain lost ground as growth stocks back in focus

TOKYO, June 10 Japanese shares clawed back lost ground to end the morning trade almost flat on Wednesday as investors rushed to buy growth and start-up stocks on continued hopes of a swift recovery from an economic contraction sparked by the coronavirus crisis.

Japan stocks hit highest in more than 3 months on economic hopes

TOKYO, June 2 Japanese shares hit a more than three-month high on Tuesday as hopes for a global economic recovery bolstered expectations for a rebound in corporate earnings, with more countries gradually reopening after coronavirus-related lockdowns.

BRIEF-Astellas Pharma Says Final Prosper Results Show Xtandi Significantly Extends Overall Survival In Men With Non-Metastatic Castration-Resistant Prostate Cancer

* FINAL PROSPER RESULTS SHOW XTANDI SIGNIFICANTLY EXTENDS OVERALL SURVIVAL IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Source text for Eikon: Further company coverage:

BRIEF-FDA Approves First Treatment For A Form Of Bladder Dysfunction In Patients As Young As 2 Yrs Of Age

* FDA APPROVES FIRST TREATMENT FOR A FORM OF BLADDER DYSFUNCTION IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OF AGE

BRIEF-Astellas Pharma Says European Medicines Agency Accepts Astellas' Marketing Authorization Application For Roxadustat

* ASTELLAS PHARMA INC - EUROPEAN MEDICINES AGENCY ACCEPTS ASTELLAS' MARKETING AUTHORIZATION APPLICATION FOR ROXADUSTAT Source text for Eikon: Further company coverage:

BRIEF-Astellas Pharma Announces Acceptance Of Xospata For Regulatory Review In China By National Medical Products Administration

* ASTELLAS PHARMA INC ANNOUNCES ACCEPTANCE OF XOSPATA (GILTERITINIB) FOR REGULATORY REVIEW IN CHINA BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan

* CONSUMMATED PURCHASE FROM ASTELLAS OF 49% OF SHARES OF AMGEN ASTELLAS BIOPHARMA K.K., JOINT VENTURE BETWEEN CO AND ASTELLAS Source text for Eikon: Further company coverage:

BRIEF-Cytomx Therapeutics Says Co And Astellas Announce Strategic Collaboration

* CYTOMX THERAPEUTICS AND ASTELLAS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP PROBODY® T-CELL ENGAGING BISPECIFIC THERAPIES FOR TREATMENT OF CANCER

Nikkei closes at 4-month low as coronavirus spreads beyond Asia

* About 98% of main board shares in red, highest ratio in 2 years

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.12%
Rohstoffe +0.08%
Industrie -0.08%
Konjunktur abhängige Waren & Dienstleistungen -0.23%
Konjunktur unabhängige Waren & Dienstleistungen -0.10%
Finanzindustrie -0.03%
Pharma +0.06%
Technologie +0.22%
Telekommunikation -0.11%